Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences, Inc. (NASDAQ:NERV) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 26,100 shares, a decrease of 54.1% from the February 28th total of 56,900 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 42,400 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NERV. StockNews.com started coverage on Minerva Neurosciences in a report on Wednesday. They set a “sell” rating for the company. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NERV stock remained flat at $1.81 during trading on Friday. 10,508 shares of the company’s stock were exchanged, compared to its average volume of 28,423. The stock has a market cap of $12.66 million, a P/E ratio of -4.11 and a beta of 0.10. The stock has a 50 day moving average price of $1.93 and a 200 day moving average price of $2.24. Minerva Neurosciences has a twelve month low of $1.42 and a twelve month high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.49. Equities research analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC increased its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.